Library

Description / Table of Contents: Abstract Objectives: Due to its low solubility and negligible metabolism, desflurane is assumed to be especially suitable for application by low-flow anaesthetic techniques. The aim of this clinical investigation was the development of a standardised dosing scheme for low-flow and minimal-flow desflurane anaesthesia. Methods: One hundred six ASA status I–II patients were assigned to six groups according to the duration of the initial high-flow phase, fresh gas flow, and fresh-gas desflurane concentration. The median age, height, body weight, and constitution of the groups was comparable. After an initial high-flow phase using 4.4 l/min, the fresh gas flow was reduced to 0.5 l/min (minimal-flow anaesthesia) or 1.0 l/min (low-flow anaesthesia). Inspired nitrous oxide concentrations were maintained at 60% to 70%. Using different standardised schemes of vaporizer settings, inspired desflurane concentrations were applied in the range from 3.4% to 8.7%, i.e., between 1 and 1.5 MAC. Inspired and expired desflurane concentrations were measured continuously by the side-stream technique and recorded on-line. Venous blood samples were taken immediately prior to induction and 45 min after flow reduction for measurement of carboxyhaemoglobin (COHb) concentration). Results: In the 10- to 15-min initial phase during which a high fresh gas flow of 4.4 l/min was used, the inspired desflurane concentration reached values in the range of 90%–95% of the fresh gas concentration. In low-flow anaesthesia this concentration could be maintained without any alteration of the vaporizer setting, whereas in minimal-flow anaesthesia with flow reduction the fresh gas concentration had to be increased by 1% to 2%: The quotient calculated by division of the inspired desflurane concentration by its fresh gas concentration (Q=CI/CF) ranges between 0.65 and 0.75 in minimal-flow and between 0.80 and 0.85 in low-flow anaesthesia. If use was made of the wide output range of the desflurane vaporizer, the inspired concentration could be increased rapidly by about 5% in 8 min, although the flow was kept constant at 0.5 l/min. Compared with its value prior to induction (2.13±1.05%), the COHb concentration decreased statistically significantly by about 0.7% during the 1st hour of minimal-flow anaesthesia (1.42±1.01%). In no case was a COHb concentration observed that exceeded threatening or even toxic values, although the soda lime was changed routinely only once a week. Conclusions: The pharmacokinetic properties of desflurane, resulting in especially low individual uptake, and the wide output range of the vaporizer facilitate the use of low-flow anaesthetic techniques in routine clinical practice. Even in minimal-flow anaesthesia, the duration of the initial high-flow phase can be shortened to min. If the flow is reduced to 1 l/min, the inspired desflurane concentration achieved in the initial high-flow phase can be maintained without any alteration of the vaporizer setting. In minimal-flow anaesthesia, however, with flow reduction to 0.5 l/min, the fresh gas concentration has to be increased to a value 1%–2% higher than the inspired nominal value. Due to the wide dialling range of the desflurane vaporizer, the amount of vapour delivered into the breathing system can be increased to about 110 ml/min even at a flow of 0.5 l/min. The large amount of agent that can be delivered into the system even under low-flow conditions, together with the very low individual uptake, results in a time-constant that is sufficiently short for the clinically required rapid increase in inspired desflurane concentrations. The short time-constant of low-flow desflurane anaesthesia improves the control of the anaesthetic concentration. If all measures are taken to safely avoid inadvertent drying out of the soda lime, there is no evidence that low-flow anaesthesia with desflurane is liable to increase the risk of accidental carbon monoxide poisoning. As the use of desflurane with high-flow anaesthetic techniques becomes wasteful, its routine clinical use from an economic and ecologic standpoint will only be justified if consistently applied with low-flow or minimal-flow anaesthesia.

Description / Table of Contents: Abstract Due to its low solubility and the high maximum concentration delivered by the vaporizer sevoflurane is especially suitable for the performance of low flow anaesthetic techniques. High flow phases for wash-in or wash-out of anaesthetic gases can be kept short, the difference between the volatile’s concentration in the fresh gas and within the breathing system is comparatively small, and the time constants are short even during low flow anaesthesia. The monitoring, required to sufficiently ensure the safety of the patients, corresponds to the current obliging technical safety standards. As compound A may accumulate in the breathing system, sevoflurane should not be administered with fresh gas flows lower than 1.0 l/min, until the scientific discussion on nephrotoxicity of this substance in humans is solved. Low flow anaesthesia guarantees a sufficient and continuous wash-out of trace gases. Thoroughly the use of sevoflurane with dry soda lime must be avoided, as this volatile in an extreme exothermic reaction is absorbed nearly totally and degraded to a considerable degree by dry carbon dioxide absorbent. The gaseous degradation products are pungent and possibly may be harmful to the patients. Only by low flow anaesthesia the use of sevoflurane will gain an economically and ecologically acceptable range of efficiency.